Neuron, Volume 101, 6 March 2019,
Alzheimer's disease (AD) is considered a polygenic disorder. This view is clouded, however, by lingering uncertainty over how to treat the quasi “monogenic” role of apolipoprotein E (APOE). The APOE4 allele is not only the strongest genetic risk factor for AD, it also affects risk for cardiovascular disease, stroke, and other neurodegenerative disorders. This review, based mostly on data from human studies, ranges across a variety of APOE-related pathologies, touching on evolutionary genetics and risk mitigation by ethnicity and sex. The authors also address one of the most fundamental question pertaining to APOE4 and AD: does APOE4 increase AD risk via a loss or gain of function? The answer will be of the utmost importance in guiding future research in AD.
AD; APOE; ASO; Alzheimer Disease; Alzheimer's Disease; Animal; Animals; Anti-sense Oligonucleotide; Apolipoprotein E; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Cardiovascular Disease; Cerebrovascular Disease; Chemistry; Degenerative Disease; Disease Course; Ethnicity; Evolutionary Genetics; Gain Of Function Mutation; Gene-based Therapy; Genetics; Groups By Sex; Human; Humans; Loss Of Function Mutation; Metabolism; Multiinfarct Dementia; Neurodegenerative Disease; Nonhuman; Pathogenesis; Pathology; Pleiotropy; Priority Journal; Review; Risk Evaluation And Mitigation Strategy; Sex; Global